S-100 and NSE as serum markers in melanoma

Anna Tofani, Raffaele P. Cioffi, Rosa Sciuto, Sandra Rea, Anna Festa, Franco Di Filippo, Renato Cavaliere, Carlo L. Maini

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

S-100 protein and neuron-specific enolase (NSE) have recently been proposed as serum markers for melanoma. In this study NSE and S-100 serum levels were assayed by commercial IRMA methods in 53 patients with melanoma. The overall prevalence of abnormal marker levels was similar for NSE (26%) and S-100 (30%). The 24 patients in stages I and II had uniformly normal S- 100 levels, but abnormal NSE levels were observed in 3 out of the 12 patients in stage II (33%) and in 1 out of 12 in stage I. NSE appears thus to be the marker of choice in the early stages, where its increase points to disease progression. In patients in stages III and IV the prevalence of abnormal values was 34% for NSE and 55% for S-100 (p = <0.05). In the latter group diagnostic sensitivity increased to 62% if isolated elevation of each marker was considered. In patients with advanced stage disease, both NSE and S-100 should be assayed.

Original languageEnglish
Pages (from-to)761-764
Number of pages4
JournalActa Oncologica
Volume36
Issue number7
Publication statusPublished - 1997

Fingerprint

Phosphopyruvate Hydratase
Melanoma
Biomarkers
S100 Proteins
Disease Progression
Serum

ASJC Scopus subject areas

  • Oncology

Cite this

Tofani, A., Cioffi, R. P., Sciuto, R., Rea, S., Festa, A., Di Filippo, F., ... Maini, C. L. (1997). S-100 and NSE as serum markers in melanoma. Acta Oncologica, 36(7), 761-764.

S-100 and NSE as serum markers in melanoma. / Tofani, Anna; Cioffi, Raffaele P.; Sciuto, Rosa; Rea, Sandra; Festa, Anna; Di Filippo, Franco; Cavaliere, Renato; Maini, Carlo L.

In: Acta Oncologica, Vol. 36, No. 7, 1997, p. 761-764.

Research output: Contribution to journalArticle

Tofani, A, Cioffi, RP, Sciuto, R, Rea, S, Festa, A, Di Filippo, F, Cavaliere, R & Maini, CL 1997, 'S-100 and NSE as serum markers in melanoma', Acta Oncologica, vol. 36, no. 7, pp. 761-764.
Tofani A, Cioffi RP, Sciuto R, Rea S, Festa A, Di Filippo F et al. S-100 and NSE as serum markers in melanoma. Acta Oncologica. 1997;36(7):761-764.
Tofani, Anna ; Cioffi, Raffaele P. ; Sciuto, Rosa ; Rea, Sandra ; Festa, Anna ; Di Filippo, Franco ; Cavaliere, Renato ; Maini, Carlo L. / S-100 and NSE as serum markers in melanoma. In: Acta Oncologica. 1997 ; Vol. 36, No. 7. pp. 761-764.
@article{210950d570444387bb9245bad1268d03,
title = "S-100 and NSE as serum markers in melanoma",
abstract = "S-100 protein and neuron-specific enolase (NSE) have recently been proposed as serum markers for melanoma. In this study NSE and S-100 serum levels were assayed by commercial IRMA methods in 53 patients with melanoma. The overall prevalence of abnormal marker levels was similar for NSE (26{\%}) and S-100 (30{\%}). The 24 patients in stages I and II had uniformly normal S- 100 levels, but abnormal NSE levels were observed in 3 out of the 12 patients in stage II (33{\%}) and in 1 out of 12 in stage I. NSE appears thus to be the marker of choice in the early stages, where its increase points to disease progression. In patients in stages III and IV the prevalence of abnormal values was 34{\%} for NSE and 55{\%} for S-100 (p = <0.05). In the latter group diagnostic sensitivity increased to 62{\%} if isolated elevation of each marker was considered. In patients with advanced stage disease, both NSE and S-100 should be assayed.",
author = "Anna Tofani and Cioffi, {Raffaele P.} and Rosa Sciuto and Sandra Rea and Anna Festa and {Di Filippo}, Franco and Renato Cavaliere and Maini, {Carlo L.}",
year = "1997",
language = "English",
volume = "36",
pages = "761--764",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - S-100 and NSE as serum markers in melanoma

AU - Tofani, Anna

AU - Cioffi, Raffaele P.

AU - Sciuto, Rosa

AU - Rea, Sandra

AU - Festa, Anna

AU - Di Filippo, Franco

AU - Cavaliere, Renato

AU - Maini, Carlo L.

PY - 1997

Y1 - 1997

N2 - S-100 protein and neuron-specific enolase (NSE) have recently been proposed as serum markers for melanoma. In this study NSE and S-100 serum levels were assayed by commercial IRMA methods in 53 patients with melanoma. The overall prevalence of abnormal marker levels was similar for NSE (26%) and S-100 (30%). The 24 patients in stages I and II had uniformly normal S- 100 levels, but abnormal NSE levels were observed in 3 out of the 12 patients in stage II (33%) and in 1 out of 12 in stage I. NSE appears thus to be the marker of choice in the early stages, where its increase points to disease progression. In patients in stages III and IV the prevalence of abnormal values was 34% for NSE and 55% for S-100 (p = <0.05). In the latter group diagnostic sensitivity increased to 62% if isolated elevation of each marker was considered. In patients with advanced stage disease, both NSE and S-100 should be assayed.

AB - S-100 protein and neuron-specific enolase (NSE) have recently been proposed as serum markers for melanoma. In this study NSE and S-100 serum levels were assayed by commercial IRMA methods in 53 patients with melanoma. The overall prevalence of abnormal marker levels was similar for NSE (26%) and S-100 (30%). The 24 patients in stages I and II had uniformly normal S- 100 levels, but abnormal NSE levels were observed in 3 out of the 12 patients in stage II (33%) and in 1 out of 12 in stage I. NSE appears thus to be the marker of choice in the early stages, where its increase points to disease progression. In patients in stages III and IV the prevalence of abnormal values was 34% for NSE and 55% for S-100 (p = <0.05). In the latter group diagnostic sensitivity increased to 62% if isolated elevation of each marker was considered. In patients with advanced stage disease, both NSE and S-100 should be assayed.

UR - http://www.scopus.com/inward/record.url?scp=0031407773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031407773&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 761

EP - 764

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7

ER -